Journal article
N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials
W Zheng, QE Zhang, DB Cai, XH Yang, Y Qiu, GS Ungvari, CH Ng, M Berk, YP Ning, YT Xiang
Acta Psychiatrica Scandinavica | WILEY | Published : 2018
DOI: 10.1111/acps.12862
Abstract
Objective: This systematic review and meta-analysis of randomized controlled trials (RCTs) examined the efficacy and safety of adjunctive N-acetylcysteine (NAC), an antioxidant drug, in treating major depressive disorder (MDD), bipolar disorder, and schizophrenia. Methods: The PubMed, Cochrane Library, PsycINFO, CNKI, CBM, and WanFang databases were independently searched and screened by two researchers. Standardized mean differences (SMDs), risk ratios, and their 95% confidence intervals (CIs) were computed. Results: Six RCTs (n = 701) of NAC for schizophrenia (three RCTs, n = 307), bipolar disorder (two RCTs, n = 125), and MDD (one RCT, n = 269) were identified and analyzed as separate gro..
View full abstractGrants
Awarded by Guangzhou Medical University
Funding Acknowledgements
The study was supported by the University of Macau (MYRG2015-00230-FHS; MYRG2016-00005-FHS) and the Affiliated Brain Hospital of Guangzhou Medical University (2016YFC0906302; 2014Y2-00105; 2015BAI13B02). MB is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (grant number 1059660).